- Home
- FFA vs MYGN Comparison
FFA vs MYGN Comparison
Compare FFA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | MYGN |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 481.6M |
| IPO Year | 2004 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FFA | MYGN |
|---|---|---|
| Price | $21.13 | $4.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 24.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $15.00 | $3.76 |
| 52 Week High | $22.31 | $10.32 |
Technical Indicators
Market Signals| Indicator | FFA | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 45.81 |
| Support Level | $20.84 | $3.93 |
| Resistance Level | $22.04 | $5.63 |
| Average True Range (ATR) | 0.29 | 0.41 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 18.85 | 48.76 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.